



The Neuropharmacology of Cannabinoids: Developments in Medicine

Guest Editor:

Dr. Tibor Markus Brunt

Department of Psychiatry,
Amsterdam UMC—University of
Amsterdam, Amsterdam, The
Netherlands

Deadline for manuscript
submissions:

31 July 2024

Message from the Guest Editor

Dear Colleagues,

The cannabis plant and cannabinoids have been of special interest to the scientific and medical communities over recent decades, since they target the endocannabinoid system and are implicated in health and disease processes. Cannabinoids have shown promise as therapeutics in cancer, inflammatory disease, and multiple sclerosis. Additionally, cannabinoids hold promise in mental health. Legislation has also propelled the research into cannabinoids in biomedical science, as many countries have largely legalized the sale and distribution of cannabis plant products. We kindly invite research groups and authors to publish articles on the neuropharmacology of cannabinoids, the endocannabinoid system, and implications for the medical sciences.

Dr. Tibor Markus Brunt
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)